INSM
Another lap around the track
Insmed came back with more TPIP data, and the message was basically: the drug is still hanging in there. In its ongoing open-label extension study in pulmonary arterial hypertension, the company said 12-month results showed sustained improvements across key efficacy measures, with no new safety surprises popping up along the way.
Why the market cares
This isn’t just academic homework. TPIP is Insmed’s once-daily treprostinil palmitil inhalation powder, and the company is trying to build a convincing case for the recently launched Phase 3 PALM-PAH trial. The latest data suggest the effect isn’t fading fast — the kind of thing investors like to see before a big, expensive late-stage readout.
Here’s the quick flavor:
- Patients staying on TPIP improved their six-minute walk distance by 55.7 meters.
- Patients who switched over from placebo improved by 54.1 meters.
- Both groups saw roughly a 60% drop in NT-proBNP, a heart-failure-related biomarker.
- About 65% of patients landed in refined low-risk territory, which sounds like the clinical version of "things are going pretty okay."
The fine print, because medicine is never simple
The study was open-label and non-placebo-controlled, so this is supportive evidence rather than the final victory lap. Still, comparable results in both continued-treatment and crossover patients make the data look more durable than a one-hit wonder.
Big picture
Insmed is trying to turn TPIP into a serious PAH franchise, and every steady update helps keep the story alive. The stock dipped 3.67% anyway, which is a reminder that biotech investors can be the hardest audience in the room.